Curis mentioned positively following Roche data at Cowen

theflyonthewall.com

Cowen said news Roche has initiated Phase Ib/II trial evaluating Erivedge in patients with relapsed/refractory acute myelogenous leukemia and relapsed/refractory, high-risk myelodysplastic syndrome is a incremental positive for Curis as it indicates Roche's commitment to developingadditional indications.

View Comments (0)